Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Sareum Holdings plc
  6. Summary
    SAR   GB00B02RFS12

SAREUM HOLDINGS PLC

(SAR)
  Report
Delayed Quote. Delayed London Stock Exchange - 07/30 11:47:54 am
9.4 GBX   +9.94%
07/30SAREUM : Shares Jump 8% on Incoming Cancer Treatment Patent
MT
07/30SAREUM : Patent Notice of Allowance for SDC-1802
PU
07/21Sareum Holdings plc Provides Financial Guidance for Fiscal 2021
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
7.55(c) 7.7(c) 7.95(c) 8.55(c) 8.7(c) Last
10 618 068 12 737 641 13 593 483 38 794 786 47 223 865 Volume
+2.03% +1.99% +3.25% +7.55% +1.75% Change
More quotes
Estimated financial data (e)
Sales 2021 0,17 M 0,24 M 0,24 M
Net income 2021 -0,93 M -1,29 M -1,29 M
Net Debt 2021 - - -
P/E ratio 2021 -2,90x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -2,15 M -2,99 M -2,99 M
Net Debt 2022 - - -
P/E ratio 2022 -1,45x
Yield 2022 -
Capitalization 292 M 406 M 406 M
Capi. / Sales 2021 1 716x
Capi. / Sales 2022 -
Nbr of Employees 6
Free-Float 95,6%
More Financials
Company
Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in... 
More about the company
All news about SAREUM HOLDINGS PLC
07/30SAREUM : Shares Jump 8% on Incoming Cancer Treatment Patent
MT
07/30SAREUM : Patent Notice of Allowance for SDC-1802
PU
07/21Sareum Holdings plc Provides Financial Guidance for Fiscal 2021
CI
07/19FTSE 100 Closes Down as Covid Cases Rise
DJ
07/19ALAN JOPE : FTSE 100 Slides as Virus Jitters Weigh
DJ
07/19SAREUM : Subscription to raise £1,000,000
PU
07/01SAREUM : Completed Covid-19 Research Project Delivers Encouraging Results
PU
06/22SAREUM : to Present at BioTrinity 2021 Conference
PU
06/15FTSE 100 Closes Higher Boosted by Strenghtened US Economy
DJ
06/15FTSE Rises, Bellway's Share Price Looks Well Supported
DJ
06/15SAREUM : Subscription to raise £1,470,000
PU
06/01SAREUM : Subscription to Raise £900,000
PU
05/28Sareum Holdings plc Expands Production Capacities for Products for the Purifi..
CI
05/25SAREUM : Trading Update
PU
05/13SAREUM : Exercise of Options and TVR
PU
More news
News in other languages on SAREUM HOLDINGS PLC
2019SAREUM HOLDINGS PLC : -25% après un placement
More news
Chart SAREUM HOLDINGS PLC
Duration : Period :
Sareum Holdings plc Technical Analysis Chart | SAR | GB00B02RFS12 | MarketScreener
Technical analysis trends SAREUM HOLDINGS PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Last Close Price 0,09 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Timothy John Mitchell Chief Executive Officer & Executive Director
Stephen B. Parker Non-Executive Chairman
John Charles Reader Executive Director & Chief Scientific Officer
Clive Birch Independent Non-Executive Director
Michael John Owen Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SAREUM HOLDINGS PLC258.76%406
GILEAD SCIENCES, INC.19.86%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.33.61%59 516
REGENERON PHARMACEUTICALS20.70%59 505
VERTEX PHARMACEUTICALS-14.71%52 296